CN101180296B - 用作Xa因子抑制剂的杂芳基-甲酸(氨磺酰基烷基)酰胺衍生物 - Google Patents

用作Xa因子抑制剂的杂芳基-甲酸(氨磺酰基烷基)酰胺衍生物 Download PDF

Info

Publication number
CN101180296B
CN101180296B CN2006800172463A CN200680017246A CN101180296B CN 101180296 B CN101180296 B CN 101180296B CN 2006800172463 A CN2006800172463 A CN 2006800172463A CN 200680017246 A CN200680017246 A CN 200680017246A CN 101180296 B CN101180296 B CN 101180296B
Authority
CN
China
Prior art keywords
propyl
ethyl
sec
piperidin
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800172463A
Other languages
English (en)
Chinese (zh)
Other versions
CN101180296A (zh
Inventor
M·瓦格纳
M·乌尔曼
V·魏纳
M·洛伦茨
A·鲍尔
M·纳扎雷
H·马特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SRL
Original Assignee
Sanofi Aventis SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis SpA filed Critical Sanofi Aventis SpA
Publication of CN101180296A publication Critical patent/CN101180296A/zh
Application granted granted Critical
Publication of CN101180296B publication Critical patent/CN101180296B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D419/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2006800172463A 2005-05-20 2006-05-06 用作Xa因子抑制剂的杂芳基-甲酸(氨磺酰基烷基)酰胺衍生物 Expired - Fee Related CN101180296B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05010929A EP1724269A1 (en) 2005-05-20 2005-05-20 Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors
EP05010929.7 2005-05-20
PCT/EP2006/004255 WO2006122661A1 (en) 2005-05-20 2006-05-06 Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor xa inhibitors

Publications (2)

Publication Number Publication Date
CN101180296A CN101180296A (zh) 2008-05-14
CN101180296B true CN101180296B (zh) 2011-10-19

Family

ID=35116052

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800172463A Expired - Fee Related CN101180296B (zh) 2005-05-20 2006-05-06 用作Xa因子抑制剂的杂芳基-甲酸(氨磺酰基烷基)酰胺衍生物

Country Status (25)

Country Link
US (1) US8088925B2 (https=)
EP (2) EP1724269A1 (https=)
JP (1) JP5027802B2 (https=)
KR (1) KR101373533B1 (https=)
CN (1) CN101180296B (https=)
AR (1) AR053730A1 (https=)
AT (1) ATE452133T1 (https=)
AU (1) AU2006246669B2 (https=)
BR (1) BRPI0610320A2 (https=)
CA (1) CA2609288C (https=)
DE (1) DE602006011156D1 (https=)
DK (1) DK1888567T3 (https=)
DO (1) DOP2006000119A (https=)
ES (1) ES2338151T3 (https=)
GT (1) GT200600211A (https=)
IL (1) IL187430A (https=)
MX (1) MX2007014274A (https=)
MY (1) MY150693A (https=)
PA (1) PA8675301A1 (https=)
PE (1) PE20061452A1 (https=)
PT (1) PT1888567E (https=)
SV (1) SV2007002534A (https=)
TW (1) TWI376377B (https=)
UY (1) UY29550A1 (https=)
WO (1) WO2006122661A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149102A1 (en) * 2011-04-29 2012-11-01 Glaxosmithkline Llc Novel compounds as wip1 inhibitors
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096303A1 (en) * 2000-06-13 2001-12-20 Eli Lilly And Company Serine protease inhibitors
EP1479678A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor xa inhibitors
US20050096309A1 (en) * 2003-09-30 2005-05-05 Wei Han Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9520044B (sl) 1994-04-26 2004-08-31 Aventis Pharmaceuticals Inc. Inhibitorji Xa faktorja
EP1217000A1 (en) * 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
HUP0304058A2 (hu) * 2001-01-30 2004-04-28 Bristol-Myers Squibb Company Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
DE10254336A1 (de) * 2002-11-21 2004-06-03 Merck Patent Gmbh Carbonsäureamide
EP1590327A1 (en) * 2002-12-23 2005-11-02 Millennium Pharmaceuticals, Inc. Ccr8 inhibitors
TW200510311A (en) * 2002-12-23 2005-03-16 Millennium Pharm Inc CCr8 inhibitors
US7491827B2 (en) * 2002-12-23 2009-02-17 Millennium Pharmaceuticals, Inc. Aryl sulfonamides useful as inhibitors of chemokine receptor activity
JP4585448B2 (ja) * 2002-12-23 2010-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 第Xa因子阻害剤としてのピラゾール−誘導体
DE10322469A1 (de) * 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096303A1 (en) * 2000-06-13 2001-12-20 Eli Lilly And Company Serine protease inhibitors
EP1479678A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor xa inhibitors
US20050096309A1 (en) * 2003-09-30 2005-05-05 Wei Han Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors

Also Published As

Publication number Publication date
DE602006011156D1 (de) 2010-01-28
DK1888567T3 (da) 2010-04-19
CA2609288A1 (en) 2006-11-23
DOP2006000119A (es) 2006-11-30
KR20080015800A (ko) 2008-02-20
PT1888567E (pt) 2010-02-09
JP5027802B2 (ja) 2012-09-19
US8088925B2 (en) 2012-01-03
ES2338151T3 (es) 2010-05-04
PA8675301A1 (es) 2006-12-07
TW200716620A (en) 2007-05-01
ATE452133T1 (de) 2010-01-15
AR053730A1 (es) 2007-05-16
GT200600211A (es) 2007-02-05
UY29550A1 (es) 2006-12-29
BRPI0610320A2 (pt) 2010-06-15
EP1888567A1 (en) 2008-02-20
AU2006246669B2 (en) 2011-10-06
SV2007002534A (es) 2007-02-19
EP1888567B1 (en) 2009-12-16
CN101180296A (zh) 2008-05-14
US20080167346A1 (en) 2008-07-10
IL187430A (en) 2013-06-27
KR101373533B1 (ko) 2014-03-12
EP1724269A1 (en) 2006-11-22
MX2007014274A (es) 2008-01-22
IL187430A0 (en) 2008-02-09
JP2008540589A (ja) 2008-11-20
CA2609288C (en) 2014-01-21
PE20061452A1 (es) 2007-01-16
WO2006122661A1 (en) 2006-11-23
AU2006246669A1 (en) 2006-11-23
HK1117157A1 (en) 2009-01-09
MY150693A (en) 2014-02-28
TWI376377B (en) 2012-11-11

Similar Documents

Publication Publication Date Title
AU2001271022B2 (en) Propane-1,3-dione derivatives
AU781862B2 (en) Heterocyclic dihydropyrimidines as potassium channel inhibitors
DE69624536T2 (de) Hydroxamsäurederivate verwendbar zur Hemmung von Gelatinase
CN104379576B (zh) 作为因子xia抑制剂用于治疗血栓栓塞疾病的取代的吡咯烷
ES2375586T3 (es) Derivados de imidazolidinona.
EP1910367A2 (en) Pyrimidine or triazine fused bicyclic metalloprotease inhibitors
CN102498091A (zh) 甘氨酸化合物
AU758237B2 (en) Thrombin inhibitors
EP1814866A2 (en) Gonadotropin releasing hormone receptor antagonists
KR20090050081A (ko) 응고 인자 IXa 억제제로서 사용하기 위한 이소세린 유도체
AU2002231235A1 (en) Acid derivatives useful as serine protease inhibitors
CN1387508A (zh) N-胍基烷基酰胺、其制备、其应用、和含有它们的药物制剂
JP2009515925A (ja) 凝固第Xa因子のインヒビターとしての新規なピロリジン誘導体
CN101180296B (zh) 用作Xa因子抑制剂的杂芳基-甲酸(氨磺酰基烷基)酰胺衍生物
CN101516833A (zh) 用作凝血因子IXa抑制剂的酒石酸衍生物
WO2005030706A1 (ja) アミド型カルボキサミド誘導体
NZ517603A (en) Azacycloalkanone serine protease inhibitors
EP1278502A2 (en) Protease inhibitors
EP2651901B1 (en) Novel 1,2- bis-sulfonamide derivatives as chemokine receptor modulators
CN101139346A (zh) 作为因子Xa抑制剂的苯并咪唑衍生物
US20040229863A1 (en) Protease inhibitors
JP2001519826A (ja) 金属プロテイナーゼ阻害剤
EP1270569A1 (en) Substituted tryptophan derivatives
EP1451175A1 (en) Thrombin inhibitors
ZA200100238B (en) Bispiperidines as antithrombotic agents.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1117157

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1117157

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20111019

Termination date: 20200506

CF01 Termination of patent right due to non-payment of annual fee